BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15936299)

  • 1. Brief review and critical examination of the use of hs-CRP for cardiac risk assessment with the conclusion that it is premature to use this test.
    Levinson SS
    Clin Chim Acta; 2005 Jun; 356(1-2):1-8. PubMed ID: 15936299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention.
    Razzouk L; Muntner P; Bansilal S; Kini AS; Aneja A; Mozes J; Ivan O; Jakkula M; Sharma S; Farkouh ME
    Am Heart J; 2009 Aug; 158(2):277-83. PubMed ID: 19619706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
    Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-sensitivity C-reactive protein in children at risk for coronary artery disease.
    Guran O; Akalin F; Ayabakan C; Dereli FY; Haklar G
    Acta Paediatr; 2007 Aug; 96(8):1214-9. PubMed ID: 17655623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002).
    Guttormsen BN; Stein JH; McBride PE; Cullen MW; Gangnon R; Keevil JG
    Am J Cardiol; 2007 Oct; 100(7):1130-3. PubMed ID: 17884376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Poor man's risk factor": correlation between high sensitivity C-reactive protein and socio-economic class in patients of acute coronary syndrome.
    Sethi R; Puri A; Makhija A; Singhal A; Ahuja A; Mukerjee S; Dwivedi SK; Narain VS; Saran RK; Puri VK
    Indian Heart J; 2008; 60(3):205-9. PubMed ID: 19240308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease.
    Aguilar D; Fisher MR; O'Connor CM; Dunne MW; Muhlestein JB; Yao L; Gupta S; Benner RJ; Cook TD; Edwards D; Pfeffer MA;
    Am Heart J; 2006 Aug; 152(2):298-304. PubMed ID: 16875914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report.
    Schnell-Inderst P; Schwarzer R; Göhler A; Grandi N; Grabein K; Stollenwerk B; Manne J; Klauss V; Siebert U; Wasem J
    Int J Technol Assess Health Care; 2010 Jan; 26(1):30-9. PubMed ID: 20059778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
    Delhaye C; Sudre A; Lemesle G; Maréchaux S; Broucqsault D; Hennache B; Bauters C; Lablanche JM
    Cardiovasc Revasc Med; 2009; 10(3):144-50. PubMed ID: 19595394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality specifications and the assessment of the biochemical risk of atherosclerosis.
    Rifai N; Warnick GR
    Clin Chim Acta; 2004 Aug; 346(1):55-64. PubMed ID: 15234636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease.
    Youssef MY; Mojiminiyi OA; Abdella NA
    Transl Res; 2007 Sep; 150(3):158-63. PubMed ID: 17761368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease.
    Papa A; Emdin M; Passino C; Michelassi C; Battaglia D; Cocci F
    Clin Chim Acta; 2008 Sep; 395(1-2):27-31. PubMed ID: 18498767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease.
    Kazemi-Bajestani SM; Ghayour-Mobarhan M; Ebrahimi M; Moohebati M; Esmaeili HA; Ferns GA
    Clin Lab; 2007; 53(1-2):49-56. PubMed ID: 17323825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
    Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
    Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High sensitive C-reactive protein, adiponectin, and urine albumin excretion rate in Chinese coronary artery disease patients with different glucose tolerance status.
    Gui MH; Hong J; Lü AK; Chen Y; Shen WF; Li XY; Ning G
    Chin Med J (Engl); 2008 Dec; 121(24):2509-16. PubMed ID: 19187587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.
    Mora S; Rifai N; Buring JE; Ridker PM
    Circulation; 2006 Aug; 114(5):381-7. PubMed ID: 16864722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [C-reactive protein in patients with coronary heart disease].
    Rajtar R; Kolasińska-Kloch W; Kloch M
    Folia Med Cracov; 2004; 45(1-2):25-32. PubMed ID: 16276823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.